Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ARMS Technology License Extended

By Labmedica staff writers
Posted on 22 Jan 2006
Under an extension to a license agreement with AstraZeneca, BTG (London, UK) and DxS Genotyping (Manchester, UK) are now able to grant licenses to the amplification refractory mutation system (ARMS).

ARMS is a simple but reliable and widely used method for the detection of genetic mutations and single nucleotide polymorphisms (SNPs). More...
The ability to grant licenses to this method now places the major rights with one licensor. The initial agreement with AstraZenca was signed in March 2004. The new extension will allow BTG and DxS to maximize the commercial value of the ARMS technology by granting licenses to companies that offer products and services related to the detection of genetic variation and thereby encourage new and novel applications.

Although more than 99% of human DNA sequences are the same, variations in DNA sequence can have a major impact on how humans respond to disease, environmental challenges, and drugs and other therapies. Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, and vascular disease. In addition, SNPs can be useful in predetermining an individual's response to drugs and can be used as markers to differentiate individuals with varying responses to treatment.

The nucleic acid diagnostic market, estimated at U.S.$1.9 billion, includes testing for infectious and genetic diseases as well as cell and tissue typing, cancer genetics, and personalized medicine. ARMS technology, noted BTG and DxS, has applications throughout this market.






Related Links:
BTG
DxS

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.